BioMed Realty Tops Out Boston Life Science Building
Takeda will occupy 600,000 square feet at the property upon its 2026 completion.
BioMed Realty has topped out 585 Kendall, a 637,000-square-foot life science building in Cambridge, Mass. Development partners include CBT Architects, Suffolk Construction, Takeda and Global Arts Liv.
The developer broke ground on the project in October 2022 and last year took out a $683.1 million construction loan from Sumitomo Mitsui Bank, according to CommercialEdge information. Completion is scheduled for next year.
Takeda Pharmaceuticals already preleased the development’s 600,000-square-foot office and lab space. The company will establish a dedicated research and development facility at the property. However, Takeda’s suburban campus will remain in Lexington, Mass., at 95 Hayden Ave.
READ ALSO: Boston Office Vacancy Up, Deliveries Higher
Located at 585 Kendall St., the proposed LEED Gold-certified building is taking shape less than 4 miles from downtown Boston and Boston Logan International Airport. The 16-story structure is also adjacent to Kendall Square.
When complete, the mid-rise will also include a 30,000-square-foot performing arts center with a 400-seat space, as well as flexible multipurpose rooms for workshops and meetings and an indoor garden developed in partnership with Global Arts Live.
Boston’s growing life science inventory
Boston leads nationally for life science construction activity, according to CommercialEdge research. Between 2019 and October 2024, almost 16.9 million square feet were underway in the market across 60 projects. In 2024 alone, more than 680,000 square feet of life science space broke ground, while deliveries amounted to 2.8 million square feet.
Last year, The Davis Cos. and Invesco Real Estate completed the second phase of The Quad, a 554,019-square-foot life science campus also in Cambridge. Scheduled to break ground this spring, the last phase will comprise 280,000 square feet.
You must be logged in to post a comment.